| Project/Area Number |
22590320
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | Nihon University (2011-2012)
Tokai University (2010) |
|---|
Principal Investigator |
TANG Xiaoyan 日本大学, 医学部, 助教 (20326036)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
MASUDA Shinobu 日本大学, 医学部, 教授 (20276794)
TAKEKOSHI Susumu 東海大学, 医学部・病態病理学, 准教授 (70216878)
OSAMURA Yoshiyuki 国際医療福祉大学, 病理学, 教授 (10100992)
MIYAGI Youhei 地方独立行政法人神奈川県立病院機構, 神奈川県立がんセンター臨床研究所分子病態学部 (00254194)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2010: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 前立腺癌 / ホルモン治療 / ソマトスタチン |
|---|
| Research Abstract |
Somatostatins are a family of cyclopeptides that act as inhibitors of various secretory processes and cell proliferation, by binding to somatostatin receptors on target cells. Somatostatin peptide agonists were introduced into clinical practice for the treatment of hormone-secreting pituitary adenomas and gastroenteropancreatic (GEP) tumours. In this study, we revealed that somatostatin receptor mRNA expression of prostate cancer cell lines can be up-regulated by DNA methylation inhibitor (5'-aza, decitabine) and histone deacetylase inhibitor (TSA), especially when we incubated those prostate cancer cells in an androgen - free medium (charcoal filtrated serum) . The results suggest that somatostatin peptide agonists may be a new treatment for hormone-resistant prostate cancer patients.
|
